CAMBRIDGE, Mass., March 2, 2011 /PRNewswire/ -- Berg Biosystems, LLC (Berg) and GNS Healthcare, Inc. (GNS), a subsidiary of Via Science, today announced that they have entered into a joint venture named MAP Biosystems, LLC (MAP) to combine their unique capabilities to accelerate advancements in critical biomedical research. MAP will utilize a combination of Berg's novel Interrogative Biology™ drug discovery platform, and GNS's patented supercomputer-driven REFS™ modeling and simulation platform, to unlock the key molecular drivers of complex diseases and drug efficacy and safety. The joint venture will focus on the repositioning of existing drugs for use in new indications with collaborators. Financial terms of the joint venture were not disclosed.
Dr. Niven R. Narain, President & CTO of Berg, said, "MAP represents to biological investigation a new paradigm of physiological understanding based upon a robust network intelligence of disease. The unique combination of unbiased systems biology and artificial-intelligence based systems engineering creates a true data driven approach to therapeutic and diagnostic development."
Narain will be speaking on applications of the Berg discovery platform and the GNS Healthcare platform in La Jolla, CA on March 2nd at the AACR-NCI sponsored conference on Systems Biology: Confronting the Complexity of Cancer. The title of the talk is "Inferring causality to unravel the network intelligence of cancer by employing a novel systems biology drug discovery platform."
The combined platforms will allow for insight into biology drawing from "omic-based", pre-clinical, and clinical data feeds employing computational biology methods to create a differential understanding of disease and health. The collaboration signifies a novel innovative step in medicine that seeks to understand causality and use it as a template for a new generation of drug development.
|SOURCE GNS Healthcare, Inc.|
Copyright©2010 PR Newswire.
All rights reserved